Johnson & Johnson’s (JNJ) Spravato, which won the backing of Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk Management Advisory Committee in February, awaits the final decision on March 4, 2019.Spravato is an intranasal form of esketamine, a glutamate receptor modulator, thought to help restore synaptic connections in brain cells in people with major depressive disorder.If approved, Spravato will offer the first new mechanism of action in 30 years, i.e., since the approval of Eli Lilly’s Prozac in 1987.Johnson & Johnson expects the drug to achieve blockbuster sales while analysts have a more conservative estimate.JNJ closed Tuesday’s (Feb.26, 2019) trading at $136.11, down 0.07%.